LINDA BADDOUR
CIK 1181151 · Executive VP & CFO · last filed 2026-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.16M
Companies
5
Total Filings
46
Lifetime Open-Market Net
-$44.75M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CYRX | Director | 68,099 | $14.71 | $1.00M | $0 | 11 | 2026-06-09 |
| WAT | Director | 2,899 | $399.70 | $1.16M | -$1.09M | 13 | 2026-02-27 |
| PRA Health Sciences, Inc. (PRAH) Delisted | Executive VP & CFO | 67,000 | $165.21 | $11.07M | -$37.87M | 11 | 2018-01-18 |
| PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted | Former Chief Financial Officer | 22,057 | — | — | -$5.79M | 8 | 2008-01-25 |
| PRA International (PRAI) Delisted | EVP and CFO | — | — | — | $0 | 1 | 2007-06-06 |
Recent Filings · Page 3 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-03-17 | CYRX | Grant (A) | — | $0 | EDGAR |
| 2021-01-06 | WAT | Grant (A) | +439 | $0 | EDGAR |
| 2020-01-03 | WAT | Grant (A) | +467 | $0 | EDGAR |
| 2019-01-04 | WAT | Grant (A) | +599 | $0 | EDGAR |
| 2018-09-05 | WAT | Grant (A) | +292 | $0 | EDGAR |
| 2018-01-18 | PRA Health Sciences, Inc. (PRAH) Delisted | Mixed | — | -$5.26M | EDGAR |
| 2017-08-31 | PRA Health Sciences, Inc. (PRAH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-08-16 | PRA Health Sciences, Inc. (PRAH) Delisted | Sell (S) | −100,000 | -$7.48M | EDGAR |
| 2017-08-10 | PRA Health Sciences, Inc. (PRAH) Delisted | Exer (M) | +100,000 | $1.17M | EDGAR |
| 2017-04-19 | PRA Health Sciences, Inc. (PRAH) Delisted | Mixed | — | -$11.28M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.